TABLE 2.
Details About Age at Onset, Duration, and Average Daily Dosage of Stimulant Treatment of the 171 Stimulant-Treated ADHD Cases, Separately by Gender
| Male (N = 130) | Female (N = 41) | Total (N = 171) | |
|---|---|---|---|
| Age at onset of stimulant treatment (y) | |||
| Mean (SD) | 10.1 (3.6) | 10.4 (3.4) | 10.2 (3.5) |
| Median (IQR) | 9.8 (7.5–12.8) | 9.4 (7.9–13.3) | 9.8 (7.5–12.8) |
| Cumulative duration of stimulant treatment (m) | |||
| Mean (SD) | 54.4 (37.2) | 48.3 (37.9) | 53.0 (37.4) |
| Median (IQR) | 45.9 (27.3–77.0) | 35.5 (16.9–72.2) | 44.8 (22.6–76.9) |
| Average daily dosage (in MEUa) | |||
| Mean (SD) | 27.8 (11.1) | 21.3 (7.4) | 26.2 (10.7) |
| Median (IQR) | 26.6 (20.0–33.1) | 20.0 (17.3–25.0) | 24.5 (19.9–31.5) |
IQR, interquartile range; MEU = methylphenidate equivalent units.
a
All abstracted stimulant dosages were converted into MEUs with the following formula: 20 mg methylphenidate = 10 mg dextroamphetamine = 56.25 mg pemoline = 10 mg methamphetamine = 10 mg levoamphetamine plus dextroamphetamine.34